AbbVie

Biotech

AbbVie links up with VC firm to map anti-inflammatory companies

While AbbVie has been garnering headlines for its cancer and neurological pipelines, the Big Pharma still has an eye on the inflammatory market.
James Waldron Nov 28, 2022 7:30am

AbbVie's Roche-rivaling bispecific gets FDA priority review

Nov 21, 2022 9:45am

AbbVie drops midphase psoriasis drug over toxicology data

Oct 31, 2022 7:40am

Alpine bails on phase 1 cancer asset after 2nd patient death

Oct 24, 2022 11:30am

AbbVie buys antibody-focused biotech DJS for $255M

Oct 20, 2022 12:40pm

Months after executive exodus, Exicure shaves off 66% of staff

Sep 27, 2022 10:15am